Search results
Results from the WOW.Com Content Network
It is an estimate of how many people who received the vaccine got the disease compared to how many people who got a placebo had the same outcome. On 2 February 2021, an interim analysis from the Moscow trial was published in The Lancet reporting an efficacy of 91.6% (95% CI , 85.6 – 95.2% ) after the second dose for all age groups, with no ...
Moderna has launched a trial of a vaccine to tackle the Beta variant or lineage B.1.351. [460] On 17 February 2021, Pfizer announced neutralization activity was reduced by two-thirds for this variant, while stating that no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made. [461]
The Food and Drug Administration (FDA) granted Pfizer full approval for the vaccine on Aug. 2021 for people ages 16 and older and granted Moderna full approval for people 18 years and older in ...
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19.
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. Moderna Inc ...
Russia has pushed ahead with its potential COVID-19 vaccine at top speed with mass public vaccinations alongside the main human trial, raising concerns among some observers that it was ...
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
People who had the jab showed a significant jump in antibody levels, even compared to the original Moderna jab. Moderna announces promising results from next-generation Covid vaccine trials Skip ...